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http:WHAT THIS PAPER ADDS
Technical innovations in stent design and cerebral protection (CPD) may improve the outcome of carotid artery
stenting (CAS). The present study reports whether interventionalists tailor their choice of stent and CPD ac-
cording to plaque echolucency or severity of stenosis in the Asymptomatic Carotid Surgery Trial-2 (ACST-2), the
largest interventional trial comparing CAS with carotid endarterectomy.Objective/Background: Several plaque and lesion characteristics have been associated with an increased risk for
procedural stroke during or shortly after carotid artery stenting (CAS).While technical advancements in stent design
and cerebral protection devices (CPD) may help reduce the procedural stroke risk, and anatomy remains important,
tailoring stenting procedures according to plaque and lesion characteristics might be a useful strategy in reducing
stroke associated with CAS. In this descriptive report of the ongoing Asymptomatic Carotid Surgery Trial-2 (ACST-2),
it was assessed whether choice for stent and use or type of CPDwas influenced by plaque and lesion characteristics.
Methods: Trial patients who underwent CAS between 2008 and 2015 were included in this study. Chi-square
statistics were used to study the effects of plaque echolucency, ipsilateral preocclusive disease (90e99%), and
contralateral high-grade stenosis (>50%) or occlusion of the carotid artery on interventionalists’ choice for stent
and CPD. Differences in treatment preference between specialties were also analysed.
Results: In this study, 831 patients from 88 ACST-2 centres were included. Almost all procedures were performed
by either interventional radiologists (50%) or vascular surgeons (45%). Plaque echolucency, ipsilateral
preocclusive disease (90e99%), and significant contralateral stenosis (>50%) or occlusion did not affect the
choice of stent or either the use of cerebral protection and type of CPD employed (i.e., filter/flow reversal).
Vascular surgeons used a CPD significantly more often than interventional radiologists (98.6% vs. 76.3%;
p < .001), but this choice did not appear to be dependent on patient characteristics.
Conclusion: In ACST-2, plaque characteristics and severity of stenosis did not primarily determine
interventionalists’ choice of stent or use or type of CPD, suggesting that other factors, such as vascular anatomy
or personal and centre preference, may be more important. Stent and CPD use was highly heterogeneous among
participating European centres.
 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2016.12.034cause of mortality and the most important cause of long-
term disability. Carotid artery stenosis is thought to cause
up to 20% of all ischaemic strokes.1 Randomised controlled
trials have shown that both carotid endarterectomy (CEA)
and carotid artery stenting (CAS) are effective in preventing
long-term stroke caused by tight carotid stenosis.2,3
Concerns remain about the higher periprocedural (<30
days) stroke rate following CAS.4 Analysis of the underlying
pathophysiologicalmechanismof these procedural strokes has
shown that most strokes occur on the day of the procedure.5
618 D.D. de Waard et al.Better patient selection and technical developments could
make stenting as safe as surgery.Technical advances in stenting
include use of cerebral protection devices (CPD), which have
been shown to reduce brain embolisation during CAS.6 Cere-
bral protection with flow-reversal devices reduce brain em-
bolisation when compared with distal filter devices.7
Stent design might also influence outcome of CAS.
Closed-cell stents are thought to prevent extrusion of
vulnerable plaque through the stent, while open-cell stents
provide more flexibility in tortuous vessels. The use of
closed-cell stent design has shown to reduce post-
procedural stroke when compared with open-cell design.8
Interventionalists will be influenced by patient anatomy
and may be influenced by other patient characteristics in
their choice of stent type and/or CPD use. Plaque echolu-
cency is thought to be a marker of plaque vulnerability and
has been associated with higher periprocedural risk.9 High-
grade contralateral disease might make proximal occlusion
devices less suitable because of relatively long endovascular
occlusion time. During filter-protected CAS, patients with
echolucent, vulnerable plaque, or preocclusive ipsilateral
disease may be at higher risk of ipsilateral stroke.10
As a consequence, although anatomical characteristics
are of great importance when choosing stent and CPD,
tailoring this choice to individual lesion characteristics might
reduce periprocedural risk in CAS. In the ongoing second
Asymptomatic Carotid Surgery Trial (ACST-2), choice of stent
and cerebral protection device is left to interventionalists’
discretion. The aim was to assess whether intervention-
alists’ choices are influenced by the reported plaque and
lesion characteristics.
METHODS
Trial protocol and patient selection
ACST-2 is an ongoing, large-scale, randomised controlled
trial comparing CEA with CAS in patients with asymptomatic
carotid stenotic disease (i.e., no ipsilateral stroke, transient
ischaemic attack or amaurosis fugax in the past 6 months).
The trial protocol has been described previously.11
Patients are eligible for ACST-2 when there is tight carotid
stenosis, revascularization is thought to be necessary, and
there is substantial uncertainty as to whether CEA or CAS is
the more appropriate treatment. Carotid imaging must be
done before randomisation in order to show that the
anatomy is appropriate for both procedures and patients
should reasonably expect to have at least 5 years of good-
quality life following intervention.
In the present study, patients who had undergone CAS
and had a verified 1-month follow-up, which included the
details of the procedure, were included. This analysis in-
cludes data collected up to December 2015, when >2000
patients had been enrolled in ACST-2.
ACST-2 was approved by the East of England Cam-
bridgeshire and Hertfordshire Ethics Committee. Individual
collaborating centres also obtained approval from their
local ethics committees before patients could be included in
the trial.CAS
ACST-2 is designed to reflect everyday clinical practice and
therefore all interventionalists participating in ACST-2
should follow their locally approved protocol for CAS. All
CE-marked stents and cerebral protection devices can be
used in ACST-2. Interventionalists performing CAS have to
have independently approved track records, documenting
their experience and success with the procedure.
Stents in the trial may be of open-cell, closed-cell, or
hybrid design. New generation, double-layer membrane
mesh stents are now also being used in ACST-2, but were
excluded from this analysis owing to low numbers at time of
data extraction. The use of CPD was recorded for all pa-
tients. Three main types of CPD being used in ACST-2
include distal filters, proximal occlusion, and distal balloon
occlusion, but distal balloon devices were excluded from
analysis of CPD type, again owing to low numbers.
Plaque echolucency, defined as GrayeWeale type I (uni-
formly anechoic or hypoechoic) or type II (predominantly
[>50%] hypoechoic)12 and the severity of ipsi- and
contralateral stenosis was determined by duplex ultraso-
nography. Angiographic data was not collected by the trial
office.Statistical analysis
Statistical analysis was performed using SPSS (Version 22,
2013; IBM, Armonk, NY, USA). Baseline characteristics of
patients with echolucent and nonecholucent plaques were
compared using a chi-square test, and a two-sample t test
was used to compare the mean of continuous variables. For
the analysis of stent design, hybrid stents were combined
with closed-cell stent design. Chi-square testing was used to
analyse whether plaque echolucency, ipsilateral pre-
occlusive disease (90e99%), and contralateral high-grade
stenosis (>50%) or occlusion influenced stent choice or
use of CPD. Differences in treatment preferences by spe-
cialty of interventionalists were also analysed. As ACST-2 is
an ongoing trial scheduled to report initial results in 2020,
influence of stent and CPD choice on procedural outcome
cannot be analysed at this stage. A p-value < .05 was
considered significant for all analyses.
RESULTS
Patient characteristics
Between January 2008 and December 2015, 2045 patients
were randomized in ACST-2. At the time of analysis, the trial
office had received and verified information on the pro-
cedure for 878 patients who underwent CEA and for 831
who had undergone CAS.
The 831 patients in this study were recruited from 88
centres in 27 countries. Interventional radiologists (IRs;
50%) and vascular surgeons (45%) performed the majority
of procedures, while the remaining 5% was performed by
cardiologists. Baseline patient characteristics are summa-
rized in Table 1. Plaque echolucency was assessed in 528/
831 (64%) patients and 250/528 (47%) of these were said to
Table 1. Baseline characteristics and plaque echolucency.
Nonecholucent (n ¼ 278) Echolucent (n ¼ 250) pa Not assessed (n ¼ 303) pb
Ipsilateral carotid diameter reduction (%)
<80 102 (36.7) 92 (36.8) .793 113 (37.3) .002
80e89 121 (43.5) 114 (45.6) 104 (34.3)
90e99 55 (19.8) 44 (17.6) 86 (28.4)
Mean  SD 79  8.5 79  8.5 .566 80  9.1 .189
Contralateral carotid diameter reduction (%)
0e49 196 (70.5) 162 (64.8) .449 159 (52.5) <.001
50e69 46 (16.5) 47 (18.8) 79 (26.1)
70e99 18 (6.5) 24 (9.6) 32 (10.6)
Occluded 18 (6.5) 17 (6.8) 33 (10.9)
Mean  SD 32  29.5 35  30.5 .235 39  35.2 .030
Side of intervention
Right 151 (54.3) 139 (55.6) .767 161 (53.1) .618
Anaesthetic technique
General 14 (5.0) 6 (2.4) .113 11 (3.6) .908
Medical history
Atrial fibrillation 13 (4.7) 21 (8.4) .082 23 (7.6) .527
Renal disease 27 (9.8) 29 (11.6) .490 27 (8.9) .426
Diabetes 88 (31.7) 73 (29.2) .541 84 (27.7) .399
Systolic blood pressure (mmHg)
>160 38 (13.7) 33 (13.2) .875 44 (14.5) .666
Mean  SD 140.6  16.5 142.0  14.9 .317 140.2  16.4 .386
Diastolic blood pressure (mmHg)
>90 57 (20.5) 49 (19.6) .796 54 (17.8) .428
Mean  SD 79.6  9.7 80.3  8.9 .372 78.9  9.4 .134
Medical therapy at randomization
Antiplatelet 259 (93.8) 229 (92.0) .403 261 (86.4) .002
Anticoagulant 17 (6.2) 25 (10.0) .102 26 (8.6) .398
Antihypertensive 250 (90.0) 227 (91.2) .816 252 (83.4) .001
Lipid-lowering 233 (84.4) 211 (84.7) .920 246 (81.5) .246
Note.
a Between patients with echolucent and nonecholucent plaques.
b Between patients with echolucency assessed and not assessed.
Table 2. Stents used.
Design Name (manufacturer) n (%)
Open Precise (CordiseCardinal) 108 (13.0)
Acculink (Abbott) 88 (10.6)
Protégé (CovidieneMedtronic) 86 (10.3)
ViVEXX (CR Bard) 7 (0.8)
Choices of Stent and Cerebral Protection 619have echolucent plaques (GrayeWeale type I or II). No
significant differences in baseline characteristics were found
between patients with echolucent and nonecholucent pla-
ques. Severity of carotid stenosis was somewhat higher, on
both ipsi- (p ¼ .002) and contralateral side (p < .001), in
patients where echolucency was not assessed.Zilver (Cook Medical) 3 (0.4)
Closed Wallstent (Boston Scientific) 200 (24.1)
XAct (Abbott) 149 (17.9)
Adapt (Boston Scientific) 10 (1.2)
Hybrid Cristallo Ideale (Medtronic) 156 (18.5)
Sinus RX (Optimed) 8 (0.9)
Mer (Balton) 1 (0.1)
Membrane Roadsaver (Terumo) 6 (0.7)
CGuard (Inspire MD) 4 (0.5)
Stent name awaited 5 (0.6)
Total 831Stent design
Thirteen different stents were used. The Wallstent (Boston
Scientific, Natick, MA, USA) was the most popular closed-
cell stent, and the Precise (CordiseCardinal, Bridgewater,
NJ, USA) the commonest open-cell stent (Table 2). Fifteen
patients were excluded from this analysis, either because
the name of the stent used is still awaited or because a
membrane mesh stent was used. In the remaining 816
patients, closed-cell stents were used more often (44%)
than open-cell stents (36%) and hybrid stents (20%). Thirty
centres, including more than one patient (range 2e19),
used the same stent in each trial patient. Of these, 17 (101
patients) used a closed stent and 13 centres (59 patients)
used an open stent only. The majority (35 centres, 582
patients) used more than one stent design and only sevenof these sites had an apparent “favourite” stent design (five
preferred closed stents and two open stents).
Choice of stent design is summarized in Table 3. Stent
choice significantly differed between specialties (p < .001),
with surgeons and cardiologists using a higher proportion of
open-cell stents compared with IRs (p ¼ .008).
Table 3. Interventionalists’ choice for open or closed design









Surgeons 143 (39.2) 221 (60.7) 364 <.001
Radiologists 124 (30.2) 286 (69.7) 410
Cardiologists 25 (59.5) 17 (40.5) 42
Plaque echolucency
Nonecholucent 85 (31.1) 188 (68.9) 273 .843b
Echolucent 74 (30.3) 170 (69.7) 244
Not assessed 133 (44.5) 166 (55.5) 299
Ipsilateral carotid diameter reduction
<90% 231 (36.5) 402 (63.5) 633 .432
90e99% 61 (33.3) 122 (66.7) 183
Contralateral carotid disease
<50% 168 (33.0) 341 (67.0) 509 .103
50e99% 98 (40.5) 144 (59.5) 242
Occluded 26 (40.0) 39 (60.0) 65
Note. Data are n (%).
a Chi-square test. Membrane mesh stents excluded from this
analysis.
b Chi-square test comparing echolucency with nonecholucency.
620 D.D. de Waard et al.Stent choice appeared not to be influenced by patients
having ipsilateral 90e99% stenosis (p ¼ .432) or by the
presence of contralateral stenosis >50% or occlusion
(p ¼ .746). Plaque echolucency also seemed to have had no
effect on stent choice (p ¼ .843). Results remained similar
when hybrid stents were analysed as a separate group.
CPDs
Ten different CPDs were used in 726/831 (87%) patients
(Table 4). Filters were commonest (580/726; 80%), followed
by proximal occlusion devices (142/726; 20%). Many (49/
88) centres that recruited more than one patient (range 2e
33) had consistent CPD usage, 37 (239 patients) using only
filter devices, and in nine (64 patients) no CPD for any trial
procedure. However, over half the trial patients (24 centres,
481 patients) were treated in centres that had a clear
variation in types of CPD. Analysis of the use of any cerebral
protection and type of CPD is summarized in Table 5. IRs
used cerebral protection less frequently than otherTable 4. Use of cerebral protection devices (CPD).
Type of CPD Name (Manufacturer) n (%)
Filter Emboshield (Abbott) 204 (24.5)
Filterwire (Boston Scientific) 159 (19.1)
Spider (MedtroniceCovidien) 112 (13.4)
Accunet (Abbott) 57 (6.9)
Angioguard (Cordis) 43 (5.2)
Fibernet (Medtronic) 1 (0.1)
Filter uncategorised 4 (0.5)
Proximal occlusion Mo.Ma Ultra (Medtronic) 114 (13.7)
Gore Flow Reversal (Gore) 28 (3.4)
Distal balloon TwinOne (Minvasys) 3 (0.4)
Viatrac (Abbott) 1 (0.1)
None used e 105 (12.6)
Total 831specialties (76% vs. 99%; p < 0.001). The decision to use
cerebral protection was not associated with any of the
lesion characteristics analysed. Plaque echolucency
(p ¼ .871) and contralateral high-grade stenosis or occlu-
sion (p ¼ .318) had no effect on the type of CPD (filter or
proximal occlusion) chosen by interventionalists.Geographical variance
Data from the six highest recruiting countries are summa-
rized in Table 6, and there was broadly consistent practice
across five of six top recruiting countries, with closed-cell
stents predominating. In Italy (n ¼ 189), a CPD was used
for all cases, echolucency was assessed most frequently
(90%), and surgeons performed almost all the interventions
(98%). In the UK, the second highest recruiting country, all
interventions (n ¼ 129) were performed by IRs, but echo-
lucency was only entered for 26% of patients and a CPD was
deployed in 74% of interventions. In Sweden (n ¼ 82), to
date, hybrid stent design was used most commonly (42%).
Clinical practice in the top-10 recruiting centres is sum-
marized in Table 7. In these centres, all recruiting >20
patients, a minimum of three different stents was used and
all centres used both open and closed stents. Highest
recruiting centres used CPD in nearly all procedures (98%),
but some used only one type of CPD (four of 10).
DISCUSSION
In this cohort study of the ongoing ACST-2 trial, where
patients were equally suitable for both CEA and CAS, the
aim was to assess any influence of plaque echolucency,
ipsilateral stenosis, and contralateral carotid disease on
interventionalists’ choice of stent design or cerebral pro-
tection during stenting.
From the results, no clear association between plaque
characteristics and treatment choice was found. This sug-
gests that interventionalists base their choice primarily on
parameters such as vascular anatomy.
Plaque echolucency is influenced by lipid-rich necrotic
core, high macrophage count, and intraplaque haemor-
rhage.13 All have been associated with a higher risk of
stroke from asymptomatic carotid stenosis,14,15 and with an
adverse outcome following CAS. In the Imaging in Carotid
Angioplasty and Risk of Stroke in Carotid Stenting study
(ICAROS), echolucent plaque (odds ratio [OR] 7.1, 95%
confidence interval [CI] 2e25; p ¼ .002) and degree of
stenosis >85% (OR 5.8, 95% CI 2e22; p ¼ .01) were in-
dependent predictors of periprocedural neurological
complications.16
For high-risk, symptomatic or echolucent, atherosclerotic
plaque, a closed stent design with a smaller free-cell area
theoretically offers better embolic protection than open-cell
stents. In a large study from the American Vascular Registry,
where plaque type was not recorded, it was concluded that
outcomes after CAS were not significantly influenced by
stent design. However, in symptomatic, but not asymp-
tomatic, patients, the open-cell stent group had a higher 30-
day stroke rate than the closed-cell group.17 Several other
Table 5. Interventionalists’ choice in cerebral protection (excluding distal balloon devices).















Surgeons 365 (98.4) 6 (1.6) 371 <.001 297 (81.6) 67 (18.4) 364 .324
Radiologists 318 (76.3) 99 (23.7) 417 246 (78.1) 69 (21.9) 315
Cardiologists 43 (100) 0 (0) 43 37 (86.0) 6 (14.0) 43
Plaque echolucency
Nonecholucent 245 (88.1) 33 (11.9) 278 .401a 201 (82.7) 42 (17.3) 243 .888a
Echolucent 226 (90.4) 24 (9.6) 250 185 (82.2) 40 (17.8) 225
Not assessed 255 (84.1) 48 (15.8) 303 194 (76.4) 60 (23.6) 254
Ipsilateral carotid diameter reduction (%)
<90 571 (88.4) 75 (11.6) 646 .096 459 (80.8) 109 (19.1) 568 .535
90e99 155 (83.4) 30 (16.2) 185 121 (78.6) 33 (21.4) 154
Contralateral carotid disease (%)
<50 462 (89.4) 55 (10.6) 517 .057 369 (80.2) 91 (19.8) 460 .584
50e99 209 (85.0) 37 (15.0) 246 164 (79.2) 43 (20.8) 207
Occluded 55 (80.9) 13 (19.1) 68 47 (85.5) 8 (14.5) 55
Note. Data are n (%).
a Chi-square test between echolucency and nonecholucency.



















Italy 189 15 14 90 2 100 24 76 XAct (38)
UK 129 20 11 26 100 74 36 64 Precise (30)
Serbia 82 2 2 67 100 98 20 80 Wallstent (38)
Sweden 82 3 3 34 68 93 37 63 Cristallo (42)
Belgium 45 6 4 87 7 96 73 27 Acculink (73)
Germany 44 8 8 82 41 84 26 74 Wallstent (50)
Note. EL ¼ echolucency; CPD ¼ cerebral protection device.
a Number of centres with at least one patient in whom echolucency was assessed.
b Including hybrid stent design.
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with closed-cell-design stents.8,18 In a dual-centre (USA and
Belgium) study of 701 patients, the difference in peri-
procedural risk between open- and closed-cell stent design
was highest for symptomatic patients (11.1% vs. 3.0%, OR
4.1; p ¼ .01) and those with echolucent plaques (8.1% vs.
2.2%, OR 3.1; p ¼ .03), supporting the argument that
closed-cell stent design provides more effective protection
of the potentially vulnerable plaque.19
In ACST-2, use of CPD is left to interventionalists’
discretion. Embolisation of debris released during the
catheterisation phase of CAS may cause stroke, and use of
CPD could help prevent this. It was found that IR does not
use CPD in 25% of cases, while vascular surgeons routinely
use CPD (98%). This difference in practice may therefore not
be due to patient characteristics.
Distal filter devices (580/726; 79.9% of total CPD)
preserve antegrade flow, but their main disadvantage is
the need to cross the lesion before opening the filter.
Smaller embolic particles can escape through the filter
pores and the filter can also occlude. Proximal occlusion
(PO) devices allow protection before crossing the stenotic
lesion, but patients may be intolerant of flow reversal in
up to 20% of cases.20 PO devices also require largersheaths, and some imaging difficulties may be caused by
flow changes in the ICA.
It was shown in the Prevention of Cerebral Embolization
by Proximal Balloon Occlusion Compared to Filter Protec-
tion during Carotid Artery Stenting study (PROFI) that new
brain lesions found on magnetic resonance diffusion
weighted imaging are less common in patients treated with
PO devices than with filters (45% vs. 87%; p ¼ .001).21 In
patients with echolucent plaques treated with distal filter-
protected CAS, Montorsi et al. found that significantly
higher rates of microembolization (on Transcranial Doppler
(TCD)) occurred during four phases of CAS (lesion crossing,
stent crossing, stent deployment, and stent dilation) when
compared with PO devices.22
In the ICAROS study, use of cerebral protection reduced
ipsilateral event rate (2.3% vs. 5.0%; p ¼ .19). However, in
those with echolucent plaques, use of CPD (of which 96%
were distal filters) was associated with an increased risk of
stroke when compared with unprotected CAS (12.5% vs.
5.2%; p ¼ .15).16
These results suggest that, for echolucent plaques, it is
desirable to initiate protection before crossing the lesion,
and PO devices may be safer than filters, unless flow
reduction is poorly tolerated.
Table 7. Clinical practice in top-10 recruiting centres.
Centre Patients (n) Inclusion period Specialty Stents used (n) Designs used CPD used (%) CPD type used
1 92 2010e2015 S 6 O, H, C 100 PO, DF
2 49 2009e2015 IR 5 O, H, C 96 DF
3 41 2008e2015 IR 7 O, H, C, M 93 PO, DF
4 35 2008e2014 S 3 O, H, C 94 PO, DF
5 33 2009e2015 IR 4 O, C 100 DF
6 33 2008e2015 IR 5 O, H, C, M 100 PO, DF
7 28 2014e2015 S 3 O, C 100 DF
8 27 2009e2015 S 4 O, H, C, M 100 PO, DF
9 22 2008e2015 S 6 O, H, C 100 PO, DF
10 21 2012e2015 S 5 O, H, C 100 PO
Note. CPD ¼ cerebral protection device; S ¼ surgeon; O ¼ open; H ¼ hybrid; C ¼ closed; PO ¼ proximal occlusion; DF ¼ distal filter;
IR ¼ Interventional Radiologists; M ¼ membrane mesh.
622 D.D. de Waard et al.Although closed-cell design and proximal occlusion de-
vices may be more appropriate for patients with high-risk
plaques and a filter device may be a better choice in pa-
tients with contralateral high-grade stenosis or occlusion,
no association was found between the characteristics under
consideration and operator choice of stent or of CPD.
This lack of association may be explained by differences
in patient anatomy or clinical practice, with each centre (or
individual) following its own specific protocol for stenting
procedures. As guidelines do not recommend the use of
certain stents or CPD according to individual patient char-
acteristics, interventionalists often use stents and CPD they
are familiar with. Filter-type CPD were introduced earlier
and interventionalists therefore have more experience with
these devices.
Choice of stent and CPD may, at least partly, be based on
financial considerations. The financial saving after shorter
hospital stay with CAS may be offset by higher device costs
when compared with CEA. In the Carotid Revascularization
Endarterectomy versus Stenting (CREST) trial, costs of CEA
were not substantially different from CAS.23 However, na-
tional reimbursement rules or hospital contracts could in-
fluence stent and CPD choice.24,25
Vascular anatomy, both in the arch and in the carotid
artery itself, is important in the choice of device and use of
protection and was assessed before entry in ACST-2.
The present study had several limitations. ACST-2 is an
ongoing trial and data on periprocedural events will not be
published until the trial is complete, so stent type and CPD
choice cannot be related to periprocedural risk. Also, there
was no knowledge of anatomical factors that might have
influenced interventionalists in their choice of stent and CPD.
Conclusion
In theACST-2, patient characteristics, like plaque echolucency,
ipsilateral preocclusive disease, or contralateral occlusion, did
not appear to determine primarily interventionalists’ choice
of stent or CPD. Stent and CPD use was highly heterogeneous
among participating European centres.
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ACST-2 COLLABORATORS
At time of accepting proofs (21/02/2017), 2419 patients
were recruited from: Austria (20 patients): Medical
University of Innsbruck (G Fraedrich, B Rantner, E Gizewski,
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Antwerp (J Hendriks, P Cras, P Lauwers, P van Scheil);
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Citadelle (G Saad); Cliniques Universitaires St-Luc
(A Peeters); A.Z St Blasius (M Bosiers). Brazil (26 patients):
University of Sao Paulo (HCFMUSP) (E da Silva, N de Luccia,
J Cid Sitrangulo Jr., A E Vallentsits Estenssoro, C Presti,
I Casella, J A Tavares Monteiro, W Campos Jr.,
P Puech-Leao). Bulgaria (5 patients): Sveta Marina Hospital
(V Petrov, C Bachvarov). Canada (16 patients): Foothills
Medical Centre (M Hill, A Mitha, J Wong). China (12
patients): Peking Union Medical College Hospital (Chang-
Wei Liu, L Bao, C Yu). Croatia (4 patients): University
Hospital Merkur (I Cvjetko, V Vidjak). Czech Republic (83
patients): Hospital Ceské Budejovice (J Fiedler, S Ostry,
L Sterba, P Kostal); St Anne’s University Hospital Brno
(R Staffa, R Vlachovsky, M Privara, Z Kriz, B Vojtisek,
P Krupa, M Reif); Regional Hospital Liberec (V Benes,
P Buchvald, L Endrych); University Hospital Ostrava Poruba
(V Prochazka, M Kuliha, D Otahal, T Hrbac); Central Military
Hospital (D Netuka, M Mohapl, F Kramier). Egypt
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H Heshmat, F Abd-Allah). Estonia (21 patients): East Tallinn
Central Hospital (V Palmiste, S Margus, T Toomsoo). France
(47 patients): Henri Mondor Hospital (J-P Becquemin); St.
Joseph Hospital (P Bergeron, T Abdulamit); Centre de
Consultation Cardiovasculaire (J-M Cardon). Germany (140
patients): Universitätsklinikum Hamburg-Eppendorf
(S Debus, G Thomalla, J Fiehler, C Gerloss, U Grzyska);
Städtisches Klinikum Karlsruhe (M Storck, E LaMacchia);
Klinikum rechts der Isar derTechnischen Universität
Muenchen (HH Eckstein, H Söllner, H Berger, M Kallmayer,
H Popert, A Zimmermann); Univeristy Hospital of Jena
(A Guenther, C Klingner, T Mayer, J Schubert, J Zanow);
University of Leipzig (D Scheinert, U Banning-Eichenseer,
Y Bausback, D Branzan, S Braünilch, J Lenzer, D Scheinert,
A Schidt, H Staab, M Ulirch); University of Dresden ‘Carl-
Gustav-Carus’ (J Barlinn, K Haase, A Abramyuk,
U Bodechtel, J Gerber, C Reeps); Hegau-Bodensee-Klinikum
(T Pfeiffer); St Franziskus-Hospital Münster GmbH
(G Torello); Park Hospital (Y Bausback, D Branzan, S Braü-
nilch, J Lenzer, D Scheinert, A Schidt, H Staab, M Ulirch);
Pius Hospital (A Cöster). Greece (71 patients): University
Hospital of Larissa (A Giannoukas, K Spanos, M Matsagkas,
S Koutias); Dept. of Vascular Surgery, Attikon University
Hospital (S Vasdekis, J Kakisis, K Moulakakis, A Lazaris,
C Liapas, E Brountzos); Democritus University Hospital
Thrace (M Lazarides); IASO Hospital (N Ioannou); General
Hospital of Athens ‘Evagelismos’ (A Polydorou); Vascular
Unit - 3rd Surgical Department (K Moulakakis, A Lazaris,
C Liapas, E Brountzos). Hungary (80 patients): Albert Szent-
Györgyi Medical Centre (B Fulop, E Fako, E Voros,
M Bodosi, T Nemeth, P Barzo, S Pazdernyik); Semmelweis
Medical University (L Entz, Z Szeberin, E Dosa, B Nemes,
Z Jaranyi, S Pazdernyia). Ireland (1 patient): St James
Hospital (P Madhaban). Israel (17 patients): Rambam
Medical Centre (A Hoffman, E Nikolsky, R Beyar). Italy (571
patients): Istituto Auxologico Italiano (R Casana, V Tolva);
Nuovo Ospedale Civile Sant’ Agostino Estense (R Silingardi,
A Lauricella, G Coppi, E Nicoloci); Santa Maria Hospital
(N Tusini, F Strozzi, E Vecchiati); Umberto I- ASO
Mauriziano (M Ferri, E Ferrero, D Psacharopulo,
A Gaggiano, A Viazzo); Vascular Endovascular Unit of
Perugia (L Farchioni, G Parlani, V Caso, P De Rangoy,
F Verzini); Circolo University Hospital (P Castelli, ML
DeLodovici, G Carrafiello, AM Ierardi, G Piffaretti); IRCCS
Policlinico San Donato (G Nano, MT Occhiuto, G Malacrida,
D Tealdi, S Steghter); University of Bologna (A Stella, R Pini,
G Faggioli); Mirano Hospital (S Sacca, M Dei Negri); IRCCS
San Martino (M Palombo, M C Perfumo); Ospedale San
Francesco di Nuoro (G Franco Fadda, H Kasemi); San
Giacomo Hospital (C Cernetti, D Tonello, A Visonà); A.C.O.
San Fillippo Neri (N Mangialardi, S Ronchey, MC Altavista);
San Giovanni Di Dio (S Michelagnoli, E Chisci); University La
Sapienza (F Speziale, L Capoccia); Policlinico Catania
(P Veroux, A Giaquinta, F Patti); University of Bari (R Pulli,
P Boggia, D Angiletta); Azienda Ospedaliera S.G Moscati
(G Amatucci, F Spinetti); St. Anna University Hospital
Ferrara (F Mascoli, E Tsolaki); Cefalù Fondazione IstitutoG. Giglio (A Giaquinta, P Veroux); Istituto Clinico Human-
ities eIRCCS (E Civilini, B Reimers); Policlinico Santa Maria
Alle Scotte (C Setacci); San Camillo Forlanini (G Pogany);
IRCCS Polinico San Matteo (A Odero); San Paolo Hospital
(F Accrocca); Universita’ Degli Studi Di Palermo (G Bajardi).
Japan (8 patients): Sendai Medical Centre (I Takashi,
E Masayuki); Kohnan Hospital (E Hidenori). Kazakhstan
(3 patients): National Scientific Centre of Surgery named
after A.N. Syzgan (B Aidashova, N Kospanov). Norway
(8 patients): Rikshospitalet University Hospital (S Bakke,
M Skjelland). Poland (71 patients): Medical University
Hospital of Warsaw (A Czlonkowska, A Kobayashi,
R Proczka, A Dowzenko, W Czepel, J Polanski, P Bialek);
Poznan University of Medical Sciences (G Ozkinis, M Snoch-
Ziólkiewicz, M Gabriel, M Stanisic); Regional Specialist
Hospital (W Iwanowski); Central Hospital Internal Affairs &
Admin Ministry (P Andziak). Portugal (3 patients): Hospital
de Santa Marta (F Bastos Gonçalves). Russia (109 patients):
Novosibirsk Research Institute of Circulation Pathology
(V Starodubtsev, P Ignatenko, A Karpenko). Serbia (251
patients): Dedinje Cardiovascular Unit (D Radak, N Aleksic,
D Sagic); Serbian Clinical Centre (L Davidovic, I Koncar,
I Tomic, M Colic). Slovak Republic (9 patients): Institute of
Medical Sciences (D Bartkoy, F Rusnak). Slovenia
(33 patients): Izola General Hospital (M Gaspirini, P Praczek,
Z Milosevic); Teaching Hospital Maribor (V Flis, A Bergauer,
N Kobilica, K Miksic, J Matela). Spain (40 patients):
Guadalajara Hospital (E Blanco, M Guerra); Hospital Clinic 1
Provincial De Barcelona (V Riambau). Sweden (212
patients): Sodersjukhuset (P Gillgren, C Skioldebrand,
N Nymen, B Berg, M Delle, J Formgren, TB Kally); Lasarettet
Helsingborg (P Qvarfordt, G Plate, H Pärson, H Lindgren);
Malmo Vascular Centre (K Bjorses, A Gottsäter,
M Warvsten, T Kristmundsson, C Forssell, M Malina, J Holst,
T Kuhme, B Sonesson, B Lindblad, T Kolbel, S Acosta).
Switzerland (44 patients): University of Basel (L Bonati,
C Traenka, M Mueller, T Lattman, M Wasner, E Mujagic,
A Von Hessling, A Isaak, P Stierli, T Eugster, L Mariani,
C Stippich, T Wolff); Cantonal Hospital Aarau (T Kahles). The
Netherlands (57 patients): University Medical Center
Utrecht (GJ de Borst, R Toorop, F Moll, R Lo, A Meershoek);
MCL Leeuwarden (A Khodadade Jahrome, AWF Vos,
W Schuiling); Haga Ziekenhuis (R Keunen); Rijnstate
Hospital (M Reijnen). United Kingdom (370 patients):
Nottingham University Hospital (S Macsweeney,
N McConachie, A Southam); Freeman Hospital (G Stansby,
T Lees, D Lambert, M Clarke, M Wyatt, S Kappadath,
L Wales, R Jackson, A Raudonaitis, S MacDonald); Sunder-
land Royal Hospital (P Dunlop, A Brown, S Vetrivel); Great
Western Hospital (M Bajoriene, R Gopi); Wythenshawe
Hospital (C McCollum, L Wolowczyk, J Ghosh, D Seriki,
R Ashleigh, J Butterfield, M Welch); Manchester Royal
Infirmary (J V Smyth); John Radcliffe Hospital (D Briley,
U Schulz, J Perkins, L Hands, W Kuker, C Darby, A Handa);
Luton & Dunstable Hospital (L Sekaran); Cheltenham
General Hospital (K Poskitt, R Bulbulia, J Morrison);
Southend University Hospital (P Guyler; I Grunwald,
J Brown, M Jakeways, S Tysoe); Kent and Canterbury
624 D.D. de Waard et al.Hospital (D Hargroves, G Gunathilagan, R Insall,
J Senaratne); Sheffield Vascular Institute (J Beard,
T Cleveland, S Nawaz, R Lonsdale, D Turner, P Gaines,
R Nair); Hull Royal Infirmary (I Chetter, G Robinson,
B Akomolafe, J Hatfield); The Royal London Hospital
(K Saastamoinen, J Crinnion); The Royal Preston Hospital
(AA Egun, J Thomas, S Drinkwater, S D’Souza, G Thomson,
B Gregory); Derriford Hospital (S Babu, S Ashley); North
Cumbria University Hospital (T Joseph); St Mary’s Hospital
(R Gibbs); Bishop Auckland Hospital (G Tebit, A Mehrzad);
Walton Centre (P Enevoldson); Royal Victoria Infirmary
(D Mendalow); James Cook Hospital (A Parry); University
Hospital of North Durham (G Tervitt); St George’s Hospital
(A Clifton). USA (1 patient): University of Toledo (M Nazzel).
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